INT79360

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 1998
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 6
Total Number 6
Disease Relevance 4.15
Pain Relevance 2.77

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Ptafr) plasma membrane (Ptafr) nucleus (Ptafr)
signal transducer activity (Ptafr)
Anatomy Link Frequency
platelet 4
DRG 1
Ptafr (Mus musculus)
Pain Link Frequency Relevance Heat
dorsal root ganglion 98 99.68 Very High Very High Very High
Dorsal horn 1 99.12 Very High Very High Very High
Substantia gelatinosa neuron 1 98.36 Very High Very High Very High
cytokine 17 98.32 Very High Very High Very High
Neuropathic pain 12 98.08 Very High Very High Very High
Brush evoked pain 48 96.56 Very High Very High Very High
Adelta 1 95.40 Very High Very High Very High
antagonist 11 95.08 Very High Very High Very High
agonist 3 94.28 High High
Pain 13 93.20 High High
Disease Link Frequency Relevance Heat
Ganglion Cysts 99 99.68 Very High Very High Very High
Syndrome 5 99.58 Very High Very High Very High
Neuropathic Pain 66 98.08 Very High Very High Very High
Acute Coronary Syndrome 21 93.80 High High
Pain 15 93.20 High High
Cv General 3 Under Development 6 89.72 High High
Nervous System Injury 58 88.88 High High
Thrombosis Related Under Development 1 84.08 Quite High
Low Back Pain 1 82.40 Quite High
Death 14 76.48 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Thus, blocking the PAFR might be a new therapeutic target for treating neuropathic pain.
Negative_regulation (blocking) of PAFR associated with neuropathic pain
1) Confidence 0.36 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2862737 Disease Relevance 1.30 Pain Relevance 0.97
Interestingly, mice lacking PAFR showed reduced phosphorylation of extracellular signal-related protein kinase (ERK), an important kinase for the sensitization of primary sensory neurons, in their DRG neurons after formalin injection.
Negative_regulation (lacking) of PAFR in DRG associated with dorsal root ganglion
2) Confidence 0.36 Published 2007 Journal J. Neurochem. Section Abstract Doc Link 17662046 Disease Relevance 1.03 Pain Relevance 1.28
PURSUIT trial demonstrates that the efficacy of eptifibatide, a IIb/IIIa platelet receptor inhibitor, increases in elderly patients who simultaneously undergo revascularization interventions.
Negative_regulation (inhibitor) of platelet receptor in platelet
3) Confidence 0.32 Published 2001 Journal Ann Cardiol Angeiol (Paris) Section Abstract Doc Link 12555632 Disease Relevance 0.33 Pain Relevance 0.24
Eptifibatide, a molecule isolated from the venom of the southeastern pygmy rattlesnake, selectively inhibits the platelet receptor IIb/IIIa.
Negative_regulation (inhibits) of platelet receptor in platelet
4) Confidence 0.05 Published 2004 Journal Am J Cardiovasc Drugs Section Abstract Doc Link 14967064 Disease Relevance 0.31 Pain Relevance 0
This paper reviews the results of 4 recent clinical trials, Platelet Receptor inhibition for Ischaemic Syndrome Management (PRISM), Platelet Receptor inhibition for Ischaemic Syndrome Management in Patients Limited to very Unstable Signs and symptoms (PRISM-PLUS), Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organisation Network (PARAGON A), and Platelet IIb/IIIa in Unstable angina Receptor Suppression Using Integrilin Therapy (PURSUIT), that have investigated the use of glycoprotein (GP) IIb/IIIa inhibitors in with non-ST-segment elevation acute coronary syndromes.
Negative_regulation (inhibition) of Platelet Receptor in Platelet associated with acute coronary syndrome, angina, syndrome and antagonist
5) Confidence 0.02 Published 1998 Journal Drugs Section Abstract Doc Link 9878986 Disease Relevance 0.58 Pain Relevance 0.13
This paper reviews the results of 4 recent clinical trials, Platelet Receptor inhibition for Ischaemic Syndrome Management (PRISM), Platelet Receptor inhibition for Ischaemic Syndrome Management in Patients Limited to very Unstable Signs and symptoms (PRISM-PLUS), Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organisation Network (PARAGON A), and Platelet IIb/IIIa in Unstable angina Receptor Suppression Using Integrilin Therapy (PURSUIT), that have investigated the use of glycoprotein (GP) IIb/IIIa inhibitors in with non-ST-segment elevation acute coronary syndromes.
Negative_regulation (inhibition) of Platelet Receptor in Platelet associated with acute coronary syndrome, angina, syndrome and antagonist
6) Confidence 0.02 Published 1998 Journal Drugs Section Abstract Doc Link 9878986 Disease Relevance 0.60 Pain Relevance 0.14

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox